Abstract
Background
Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce. The aim of this study was to identify prognostic factors, complications, and therapeutic effects in patients with immune-mediated scleritis.
Methods
Patients with diagnosis of scleritis and a follow-up time of 5 years were identified. Systemic disease, laboratory investigations, type of scleritis, disease activity, therapy, and complications were recorded. The study design was a retrospective, non-comparative, interventional case series.
Results
Systemic disease was identified in 15 (37 %) patients at presentation and in 18 (45 %) after 5 years. Rheumatoid arthritis (15 %), granulomatosis with polyangiitis (7.5 %), and polychondritis (7.5 %) were the most predominant disorders. Persistent scleritis (>5 years) was associated with systemic disease (66 vs. 6 %; p < 0.05) and positive auto-antibodies (48 vs. 23 %; p = 0.18). Control of ocular inflammation was achieved in 38 of 40 (95 %). Prednisone (14 patients) and/or methotrexate (8) were the predominant drugs to control persistent disease. Complications included interstitial keratitis (2), inflammatory astigmatism (2), corneal melt (3), macular edema (6), and severe systemic disease (5).
Conclusion
The presence of systemic disease and positive auto-antibodies are associated with persistent scleritis. Immunosuppressive agents allow control of scleritis, but may contribute to severe systemic complications.
Similar content being viewed by others
References
Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA (2004) Evaluation of patients with scleritis for systemic disease. Ophthalmology 111:501–506
Sainz de la Maza M, Foster CS, Jabbur NS (1995) Scleritis associated with systemic vasculitic diseases. Ophthalmology 102:687–692
Watson PG, Heyreh SS (1976) Scleritis and episcleritis. Br J Ophthalmol 60:163–191
Bernauer W, Ficker LA, Watson PG, Dart JKG (1995) The management of corneal perforations associated with rheumatoid arthritis. Ophthalmology 102:1325–1337
Sainz del la Maza, Jabbur NS, Foster CS (1993) An analysis of therapeutic decisions for scleritis. Ophthalmology 100:1372–1376
Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS (2012) Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 119:43.50
Wieringa WG, Sieringa JE, Dam-van Loon NH, Los LI (2013) Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology 120:379–386
McCluskey PJ, Wakefield D (1996) Scleritis and Episcleritis. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity, 1st edn. Mosby, St. Louis, pp 642–662
Arellanes-Garcia L, del Carmen Preciado-Delgadillo M, Graza-Leon M (2011) Refractive changes in patients with autoimmune scleritis. J Ophthalmol Inflamm Infect 1:173–175
Meller D, Böker T (1997) Complications of misdiagnosed and inadequately treated necrotizing scleritis studied by ultrasound biomicroscopy and computerized corneal topography. Int Ophthalmol 21(1):35–37
Tuft SJ, Watson PG (1991) Progression of scleral disease. Ophthalmology 98:467–471
Proprietary interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work has not previously been presented.
Rights and permissions
About this article
Cite this article
Bernauer, W., Pleisch, B. & Brunner, M. Five-year outcome in immune-mediated scleritis. Graefes Arch Clin Exp Ophthalmol 252, 1477–1481 (2014). https://doi.org/10.1007/s00417-014-2696-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-014-2696-1